Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Remdesivir Clear all
Completed No phase listed Observational Results available

PK and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the US

NCT04582266
View directory record Official record
Conditions
COVID-19
Interventions
Remdesivir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
10
States / cities
Los Angeles, California • Denver, Colorado • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Jul 21, 2026, 11:19 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of Remdesivir in Participants Below 18 Years Old With COVID-19

NCT04431453
View directory record Official record
Conditions
COVID-19
Interventions
Remdesivir
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
Up to 18 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • Madera, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Jul 21, 2026, 11:19 AM EDT
Completed No phase listed Observational

Real World Study of COVID-19 in a Flyover Region

NCT04962347
View directory record Official record
Conditions
Covid19
Interventions
Not listed
Lead sponsor
Tulane University
Other
Eligibility
18 Years to 120 Years
Enrollment
1,800 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Jul 21, 2026, 11:19 AM EDT
Recruiting Phase 2 Interventional

Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals

NCT06817889
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Autoimmune Disease, Respiratory Syncytial Virus Infection
Interventions
Remdesivir, Survey Administration, Biospecimen Collection, Nasal Swab
Drug · Other · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Duarte, California • Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jul 21, 2026, 11:19 AM EDT
Approved For Marketing No phase listed Expanded access

Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)

NCT04323761
View directory record Official record
Conditions
SARS-CoV2 Infection
Interventions
Remdesivir
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
12 Years and older
U.S. locations
165
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 130 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Jul 21, 2026, 11:19 AM EDT
Completed Phase 3 Interventional Results available

Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)

NCT06729593
View directory record Official record
Conditions
Covid19
Interventions
Remdesivir, Remdesivir Placebo, Corticosteroid
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
40
States / cities
Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Jul 21, 2026, 11:19 AM EDT
Terminated Phase 3 Interventional

Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients

NCT04672564
View directory record Official record
Conditions
Coronavirus Disease 2019
Interventions
Carrimycin, Placebo
Drug
Lead sponsor
Shenyang Tonglian Group CO., Ltd
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Amarillo, Texas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Jul 21, 2026, 11:19 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment

NCT04292730
View directory record Official record
Conditions
COVID-19
Interventions
Remdesivir, Standard of Care
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
12 Years and older
Enrollment
1,113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
106
States / cities
Anaheim, California • Berkeley, California • Burlingame, California + 76 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Jul 21, 2026, 11:19 AM EDT
Not listed Phase 1 Interventional

Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831

NCT04480333
View directory record Official record
Conditions
Covid19, Corona Virus Infection, Severe Acute Respiratory Syndrome, Severe Acute Respiratory Infection, Severe Acute Respiratory Syndrome (SARS) Pneumonia, Severe Acute Respiratory Syndrome of Upper Respiratory Tract, Neurodegeneration, Neuroinflammatory Response
Interventions
Drug: NA-831 - 0.10 mg/kg, Placebo- 0.10 mg/kg, Drug: NA-831 - 0.20 mg/kg, Placebo- 0.20 mg/kg, Drug: GS-5734 - 1.00 mg/kg, Placebo- 1.00 mg/kg, Drug: GS-5734 - 2.00 mg/kg, Placebo- 2.00 mg/kg, Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg), Placebo 0.10 mg + 1.00 mg/kg, Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg), Placebo 0.20 mg + 2.00 mg/kg
Drug · Combination Product
Lead sponsor
Biomed Industries, Inc.
Industry
Eligibility
21 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Sunnyvale, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Jul 21, 2026, 11:19 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Researchers At UC San Diego Are Learning About the Benefits of Human Milk and How It Influences Infant and Child Health

NCT05553743
View directory record Official record
Conditions
Breastfeeding, COVID-19 Infection, COVID-19 Vaccine, Remdesivir, Antibiotics
Interventions
COVID-19 Exposure, Antibiotic
Biological · Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2040
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Jul 21, 2026, 11:19 AM EDT
Terminated Phase 2 Interventional

Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19

NCT04410354
View directory record Official record
Conditions
COVID-19
Interventions
Merimepodib, Matching Placebo, Remdesivir
Drug
Lead sponsor
ViralClear Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
10
States / cities
Phoenix, Arizona • Fort Lauderdale, Florida • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Jul 21, 2026, 11:19 AM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19)

NCT04745351
View directory record Official record
Conditions
COVID-19
Interventions
Remdesivir, RDV Placebo, Standard of Care
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
12 Years and older
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
41
States / cities
Birmingham, Alabama • Mobile, Alabama • Eureka, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Jul 21, 2026, 11:19 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)

NCT04292899
View directory record Official record
Conditions
COVID-19
Interventions
Remdesivir, Standard of Care
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
12 Years and older
Enrollment
4,891 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
106
States / cities
Anaheim, California • Berkeley, California • Burlingame, California + 76 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2020 · Synced Jul 21, 2026, 11:19 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation

NCT04539262
View directory record Official record
Conditions
COVID-19
Interventions
Remdesivir (RDV), Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
28
States / cities
Mesa, Arizona • Tucson, Arizona • Bakersfield, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Jul 21, 2026, 11:19 AM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting

NCT04501952
View directory record Official record
Conditions
COVID-19
Interventions
RDV, Placebo to Match RDV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
12 Years and older
Enrollment
584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
92
States / cities
Chandler, Arizona • Tucson, Arizona • Eureka, California + 78 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Jul 21, 2026, 11:19 AM EDT
No Longer Available No phase listed Expanded access

Expanded Access Remdesivir (RDV; GS-5734™)

NCT04302766
View directory record Official record
Conditions
Coronavirus Disease 2019
Interventions
Remdesivir
Drug
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
Not listed
U.S. locations
14
States / cities
San Diego, California • Jacksonville, Florida • Fort Benning, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Jul 21, 2026, 11:19 AM EDT
Recruiting Phase 3 Interventional

A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

NCT07013474
View directory record Official record
Conditions
COVID-19 Infection
Interventions
ibuzatrelvir, remdesivir, placebo for ibuzatrelvir, placebo for remdesivir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
65
States / cities
Canoga Park, California • Granada Hills, California • La Jolla, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 21, 2026, 11:19 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia

NCT04409262
View directory record Official record
Conditions
COVID-19 Pneumonia
Interventions
Remdesivir, Tocilizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years and older
Enrollment
649 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
38
States / cities
Phoenix, Arizona • Chula Vista, California • Irvine, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2022 · Synced Jul 21, 2026, 11:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First-in-Human Study of Orally Administered GS-441524 for COVID-19

NCT04859244
View directory record Official record
Conditions
COVID-19
Interventions
GS-441524
Drug
Lead sponsor
Copycat Sciences LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Jul 21, 2026, 11:19 AM EDT